drugset / Trial / NCT04123613
Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.
Timeline
- Start
- 2019-12-17
- Primary completion
- 2022-03-16
- Completion
- 2022-03-16
Outcome
Met primary endpoint
release “DM199 is demonstrating clinically meaningful improvements in kidney function in Cohorts 1 and 2” diamedica.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rinvecalinase Alfa | Protein / enzyme biologic | 2 ug/kg | Subcutaneous |
| Subject | Rinvecalinase Alfa | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |